MIAMI, April 1, 2008 (PRIME NEWSWIRE) -- Galea Life Sciences, Inc. (Pink Sheets:GLSN) announced that its BioSource Therapeutics, Inc. (BST) subsidiary will present its clinical policy abstract emphasizing the value of nutrition and protein in combating muscle and skeletal wasting at the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), May 28-30, in Toulon, France. BST is the maker of Nutraplete(tm) Therapeutic Drink Mix, the first dietary supplement product designed specifically for people living with HIV/AIDS.
"Galea and BST are honored to be invited to this important world event," said Dr. Robert Keller, MD, MS, FACP, AAHIVS, Clinical Advisor and head of BST's Scientific Advisory Board. "Knowledge shared at ISHEID is used in the global fight against AIDS, and we believe the medical and scientific communities involved in this fight should be aware of the benefits that Nutraplete can deliver. We are grateful to have this opportunity."
The clinical policy abstract is titled, "Micronutrients and High Protein Supplementation in the Treatment of Catabolic Cachexia and the Improvement in the Quality of Life in the Era of HAART," (Abstract #A-081-0008-00269). Presenting author, Dr. Peggy Achenbach, discusses the evidence-based utilization of micronutrient supplementation during HAART to enhance CD4 count, decrease viral load and decrease HIV/AIDS associated involuntary muscle loss.
Catabolic Cachexia is a term used to describe the gradual breakdown of muscle and skeletal components associated with disease. Nutraplete was formulated to address micronutrient deficiencies found in patients diagnosed with HIV infection and serve as a requisite adjunct to Highly Active Antiretroviral Therapy (HAART), the prescribed course of treatment for people living with HIV/AIDS.
Dr. Keller added, "Addressing and correcting nutritional and antioxidant deficiencies caused by the virus should be considered a critical component in treating HIV/AIDS in conjunction with HAART. Nutraplete is the first and most complete nutritional supplement designed specifically for HIV/AIDS that addresses many of the inherent nutritional and antioxidant problems associated with this disease."
Nutraplete combined with HAART may help ease side effects like diarrhea and nausea, symptoms that can decrease HIV/AIDS patients' adherence to certain drug regimens. The various ingredients in Nutraplete may also help to reduce oxidative stress, support the immune system, prevent muscle loss and rebuild essential muscle by providing important micronutrients, protein and enzymes.
About ISHEID
The International Symposium on HIV and Emerging Infectious Diseases (ISHEID) is convening the 15th International Symposium in Toulon, France, May 28-30, 2008. With thousands of attendees expected, this meeting promises to be one of the largest gatherings of HIV/AIDS professionals and community stakeholders in Europe. The Conference emphasizes scientific excellence and inquiry, encourages individual and collective action and dialogue, and fosters social accountability. For more information: http://www.isheid.com.
Jeannie Gibbs, National HIV/AIDS Community Liaison at BST, will be covering the proceedings of ISHEID in the forthcoming issue of The AIDS Institute's ActionLink Journal.
About the AIDS Institute
The AIDS Institute is a leading national public policy research, advocacy and education non-profit organization located in Washington DC and Tampa, Florida. Affiliated with the Division of Infectious Diseases and Tropical Medicine at the University of South Florida College of Medicine, The AIDS Institute focuses on HIV/AIDS while incorporating work on related healthcare issues such as Hepatitis and other infectious and chronic diseases. http://www.theaidsinstitute.org
About Nutraplete
Nutraplete is the first therapeutic dietary supplement designed specifically for people living with HIV/AIDS. It is a multi-nutritional supplement designed to address AIDS Wasting Syndrome. Nutraplete is a "functional food" that encourages the restoration of lean body mass, can decrease oxidative stress, and assist immune function. Nutraplete is available by prescription, and has started the application process for inclusion with Medicaid and AIDS Drugs Assistance Program (ADAP) formularies. Nutraplete is distributed exclusively in the U.S. by Allion Healthcare, Inc. (NASDAQ: ALLI) under its MOMS Pharmacy trade name. www.momspharmacy.com.
For more information: www.nutraplete.com
About Galea Life Sciences, Inc.
Galea Life Sciences, Inc. (Pink Sheets: GLSN) is currently a non-reporting over-the-counter, publicly traded company. GLSN identifies and acquires new and innovative nutraceutical product and dietary supplement companies with outstanding growth potential. GLSN's focus is in the emerging scientific field of advanced nutritional supplements designed to support traditional medical treatments and therapies. BioSource Therapeutics, Inc. (BST), a GLSN subsidiary, is an entrepreneurial life sciences company. BST specializes in the formulation, manufacturing, marketing and distribution of innovative dietary supplements that benefit people undergoing medical treatments and therapies.
Certain statements in this release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words ``forecast,'' ``project,'' ``intend,'' ``expect'' ``should,'' ``would,'' and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (finance or operating) or achievements to differ from future results, performance (financing and operating) or achievements expressed or implied by such forward-looking statements. Statements herein express management's beliefs and expectations regarding future performance and are forward-looking and involve risks and uncertainties, including, but not limited to, the ability to negotiate outstanding prior debts of acquired companies; properly identify acquisition partners; adequately perform due diligence; manage and integrate acquired businesses; react to quarterly fluctuations in results; raise working capital and secure other financing; respond to competition and rapidly changing technology; deal with market and stock price fluctuations; and other risks.